Navigation Links
SINOL USA, Inc. and Strategic Pharmaceutical Advisors, Inc. to Enter a Marketing Agreement for SINOL Nasal Spray

Strategic Pharmaceutical Advisors (SRxA) and Sinol USA, Inc. announced the signing of a Memorandum of Understanding signifying their intent to enter into a marketing agreement for SINOL Nasal Spray, an all natural, capsaicin-based product for fast relief from allergy and sinus congestion and headaches of all types.

Washington, DC, and Newtown, CT (PRWEB) July 1, 2008 -- Strategic Pharmaceutical Advisors (SRxA) and Sinol USA, Inc., announced today the signing of a Memorandum of Understanding signifying their intent to enter into a marketing agreement for SINOL Nasal Spray. Under the proposed terms of the agreement SRxA will lead the worldwide educational and information support of SINOL Nasal Spray to professional and consumer audiences.

Headquartered in Newtown Connecticut, Sinol USA Inc. is a healthcare company dedicated to the Development of products using all natural ingredients. Available without a prescription, SINOL Nasal Spray formulations use clean, old fashioned ingredients for fast relief from allergy and sinus congestion and headaches of all degrees and types.

SRxA is a health education and strategic planning firm with world-renowned physicians as its partners and advisors. As part of this agreement, SRxA will develop programming tailored to the education of professional and consumer audiences and deliver it in a variety of media appropriate for each target audiences. Strategic Pharmaceutical Advisors is headquartered in Washington, DC, with offices in London and Hong Kong.

In announcing this collaboration, Paul Carpenter, Chief Executive Officer of Sinol USA, Inc. noted, "SINOL Nasal Sprays have caught the attention of U.S. medical practitioners in a very short period of time. With this collaboration, we now look forward to expanding our US base and reaching an international physician audience through the proven expertise and global sphere of influence of Strategic Pharmaceutical Advisors."

Dr. Christos S. Efessiou, Strategic Pharmaceutical Advisors' Chief Executive Officer, commented "The option of providing the public with an all natural, non-prescription alternative for relief from allergy-related congestion and headaches, impressed our Team enough to seek an active partnership in SINOL. My colleagues and I are excited at the possibilities that this partnership will offer to healthcare professionals and to allergy and headache sufferers."

Sinol USA is presently working with Strategic BioSciences, a SRxA affiliate, in a pioneering new product reformulation agreement which is expected to offer significant advantages to SINOL users. The two companies expect to announce this agreement in the near future.

For more information please visit: and

# # #

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Response Biomedical Corporation Announces Strategic Partnership with Roche Diagnostics To Commercialize Cardiovascular Tests
2. Honour Healthcare and River Logic Deliver Comprehensive Integrated Business Planning Solution Through Strategic Alliance
3. American Well and Microsoft Enter Into a Strategic Collaboration to Bring Healthcare to Peoples Homes
4. StayWell Custom Communications Announces Strategic Alliance With HealthMedia
5. TetraQ and Q-Pharm form strategic alliance
6. Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals
7. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
8. Nonin(R) Medical Announces Strategic Relationship With Microsoft and its Microsoft HealthVault Platform
9. Xceed Molecular Licenses Signature from Moffitt Cancer Center and Adds Moffitt to Strategic Collaborator Program
10. Escalon(R) Enhances Position Within IVD Reagent Market with Strategic Acquisition of JAS Diagnostics
11. Cline Davis & Mann Launches Platform Advisors(TM), a New Division to Provide Integrated Strategic and Scientific Consulting Services for the Pharmaceutical, Biotechnology, and Medical Device Industry
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity ... have come together on Thanksgiving Day to share the things that they are ... the Serenity Point YouTube channel, patients displayed what they wrote on index cards, ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
(Date:11/26/2015)... ... , ... The Catalent Applied Drug Delivery Institute today announced ... form selection in early phase drug development. The first of these is to ... the UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating their record books ... their 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the PRMA ... rebuild lives and it’s an honor to have served all of these women.” , ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
(Date:11/25/2015)... , Nov. 26, 2015  The total global healthcare industry ... over 2015-2016. Latin America has the ... , (excluding Japan ), is second with ... continues to face increased healthcare expenditure. In 2013-2014, total government ... from 43.5% in 2008-2009 to 41.2% in 2013-2014. In real ...
(Date:11/25/2015)... , Nov. 25, 2015 On Tuesday, ... federal bellwether trial against Wright Medical Technology, Inc. ... their Conserve metal-on-metal hip implant device, awarded $11 ... a two week trial and three days of ... hip device was defectively designed and unreasonably dangerous, ...
Breaking Medicine Technology: